 |
Tampa-based 1AB is handling Moderna Therapeutics, which on March 16 began the first US clinical trial for a coronavirus vaccine
The Cambridge, MA-based biotech's MRNA-1273 product is participating in the dosed Phase 1 study conducted by the National Institutes of Health under its Investigational New Drug application.
The study of 45 healthy adults is expected "to provide important information about safety and immunogenicity," according to Tal Zaks, chief medical officer at Moderna, which is preparing for a Phase 2 study based on the data collected from Phase 1.
Moderna has strategic alliances with Merck, AstraZeneca, Pentagon's Defense Advanced Research Projects Agency and Biomedical Advanced Research and Development Authority, which is part of the Dept. of Health and Human Services.
Katie Engleman, 1AB managing director handles the Moderna push. She joined the life sciences strategic communications shop in 2018 following a 10-year stint at W2O's Pure Communications unit.
A breakthrough is not successful merely because it works. It succeeds when people and health systems can actually use it.
Jim Weiss, founder & chairman of Real Chemistry, has joined the board of ICR Inc. as it steps up its healthcare capital markets offering.
Ruder Finn has hired Kelly Yoder, who spent a dozen years at Weber Shandwick rising to North America health lead, as managing director, global head of health & life sciences.
ICR has named John Capodanno head of US healthcare corporate communications and Matthew Willey managing director in its medical technology and diagnostics practice. 
April is National Minority Health Month, spotlighting the urgency to improve health outcomes in communities of color.
